Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

The biotech giant's most important drug is under a microscope and it doesn't look pretty.

Should Biogen Investors Be Extra Nervous Right Now?

The biotech's misstep in Alzheimer's disease proved costly for shareholders last month.

Why Biogen Stock Tanked in March

The clinical-stage gene therapy company got some love from biotech giant Biogen last month.

Why Nightstar Therapeutics Stock Skyrocketed 71% in March

bluebird bio

Novartis

A thousand gene therapies in development could get a lot more attention if these two live up to expectations this year.

2 Blockbuster Gene Therapy Programs to Watch in 2019

Amgen

Axsome Therapeutics

Biogen threw in the towel with once-promising Alzheimer's disease drug aducanumab. But these three late-stage pipeline candidates could potentially still emerge as winners.

3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

Biogen stock tumbled Wednesday after Novartis gained approval for a rival multiple sclerosis treatment, dubbed Mayzent. Multiple sclerosis drugs comprise a huge portion of Biogen's sales.

The Hits Just Keep Coming For Biogen As Rival Gains MS Drug Approval

The biotech nosedives after disappointing results for everyone involved in the Alzheimer's space.

Biogen's Bad News for Everyone

CVS Health

Intuitive Surgical

What do a beaten-down biotech, a giant pharmacy chain, and a robotic surgical systems maker have in common? They could all be great stocks to buy.

Healthcare Stocks to Buy Right Now

Just two weeks ago I looked at Biogen as it was "adding to the pipeline" with the acquisition of Nightstar Therapeutics  in an $800 million deal

Biogen - Pipeline Setback Looks To Create An Opportunity

Most biotech drugs focus on clearing plaques from brain cells, but restoring patients' sleep quality is also proving to be necessary.

1 Surprising Reason Alzheimer's Drugs Remain So Elusive

A Biogen Inc. (NASDAQ: BIIB) filing with the Securities and Exchange Commission (SEC) indicates that it intends to buy back a sizable amount of stock. This comes after the biotech giant lost roughly one-third of its market cap following a discontinued Alzheimer’s disease trial.

How Biogen Is Dealing With Discontinued Alzheimer’s Trial

Biogen said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Shares of Biogen Inc. bounced 1.7% in premarket trade Monday, after the drugmaker disclosed that it set a new $5.0 billion stock repurchase program, without an expiration date.

Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge

New Jersey resident Jeff Borghoff, a patient in Biogen's failed clinical trial for Alzheimer's, was left heartbroken when he heard the news the experimental treatment was unlikely to work.

Failed Alzheimer's trial leaves families and patients heartbroken. Medical community reels

Biogen Inc. shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab.

Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

Biogen and Japanese pharma Eisai announced a new study in Alzheimer's disease treatment Friday following a high-profile failure on Thursday that sent Biogen stock into a tailspin.

Biogen Won't Retreat From Alzheimer's, But Stock Keeps Slipping

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

Biogen Stock Crashes on Termination of Alzheimer's Studies

SVB Leerink analysts cut their price target on shares of Biogen Inc.  to $247 from $341 on Friday.

Biogen stock price target cut to $247 from $341 at SVB Leerink

Analysts at UBS on Friday downgraded shares of Biogen Inc.  to neutral from buy, while cutting their price target on the stock to $242 from $395.

Biogen stock downgraded to neutral from buy at UBS

Now that the riskiest asset in biotech is off the table, it's time to reconsider an industry legend that's down 30% on Thursday.

Is Biogen a Bad-News Buy Now?

Biogen Inc. shares were crushed in Thursday’s session after the firm announced that it would be discontinuing its late-stage trial for Alzheimer’s disease.

Why This Alzheimer’s Study Is Crushing Biogen Shares

Biogen stock collapsed in premarket trades Thursday.

Biogen Crashes After Scrapping Key Alzheimer's Treatment Studies

Shares of neuroscience company Biogen Inc lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer
 read more

Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study

Biogen is down more than 25% on 21 March 2019, shedding close to $20 billion in market capitalization, as the company announced the shocking news that it was going to discontinue the Phase 3 trials for its drug to treat Alzheimer's disease.

Should You Buy The Drop In Biogen?

The biotech throws in the towel on a drug that some thought could be a game changer in treating Alzheimer's disease. And it's left with a challenging future.

News for Biogen Stock (BIIB)